JP7033066B2 - 免疫寛容応答を生成する組成物及び方法 - Google Patents

免疫寛容応答を生成する組成物及び方法 Download PDF

Info

Publication number
JP7033066B2
JP7033066B2 JP2018535329A JP2018535329A JP7033066B2 JP 7033066 B2 JP7033066 B2 JP 7033066B2 JP 2018535329 A JP2018535329 A JP 2018535329A JP 2018535329 A JP2018535329 A JP 2018535329A JP 7033066 B2 JP7033066 B2 JP 7033066B2
Authority
JP
Japan
Prior art keywords
tgf
cells
sulfate
composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018535329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504832A5 (enExample
JP2019504832A (ja
Inventor
コーヘン、スマダール
モンソネゴ、アロン
Original Assignee
ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー filed Critical ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー
Publication of JP2019504832A publication Critical patent/JP2019504832A/ja
Publication of JP2019504832A5 publication Critical patent/JP2019504832A5/ja
Application granted granted Critical
Publication of JP7033066B2 publication Critical patent/JP7033066B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018535329A 2016-01-07 2017-01-05 免疫寛容応答を生成する組成物及び方法 Expired - Fee Related JP7033066B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275827P 2016-01-07 2016-01-07
US62/275,827 2016-01-07
PCT/IL2017/050013 WO2017118979A1 (en) 2016-01-07 2017-01-05 Compositions and methods for generating immunotolerant responses

Publications (3)

Publication Number Publication Date
JP2019504832A JP2019504832A (ja) 2019-02-21
JP2019504832A5 JP2019504832A5 (enExample) 2019-12-12
JP7033066B2 true JP7033066B2 (ja) 2022-03-09

Family

ID=59273512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535329A Expired - Fee Related JP7033066B2 (ja) 2016-01-07 2017-01-05 免疫寛容応答を生成する組成物及び方法

Country Status (7)

Country Link
US (1) US11123404B2 (enExample)
EP (1) EP3400074B1 (enExample)
JP (1) JP7033066B2 (enExample)
KR (1) KR20180104646A (enExample)
CN (1) CN109069875B (enExample)
IL (1) IL260436B2 (enExample)
WO (1) WO2017118979A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035413B1 (ru) 2013-06-13 2020-06-10 Ордженисис Лтд. Популяции клеток, способы трансдифференцировки и способы их применения
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
SG11201911256UA (en) 2017-05-08 2020-01-30 Orgenesis Ltd Transdifferentiated cell populations and methods of use thereof
WO2019171377A1 (en) * 2018-03-06 2019-09-12 Orgenesis Inc Three dimensional clusters of transdifferentiated cells, compositions and methods thereof
JP2022506154A (ja) * 2018-11-01 2022-01-17 バークレー ライツ，インコーポレイテッド マイクロ流体環境において生体細胞をアッセイする方法
CN109771638A (zh) * 2018-12-28 2019-05-21 中国人民解放军陆军军医大学第一附属医院 一种免疫耐受剂
WO2024080183A1 (ja) * 2022-10-14 2024-04-18 国立大学法人東海国立大学機構 糖鎖複合体、薬物担体、及びドラッグデリバリーシステム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043050A2 (en) 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2011078990A1 (en) 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprising hyaluronan and at least one t cell induction agent

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178361A (en) 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
GB9722604D0 (en) 1997-10-28 1997-12-24 Cancer Res Campaign Tech Heparin-binding growth factor derivatives
US6388060B1 (en) 1998-11-06 2002-05-14 Vascular Therapeutics Inc. Process for the sulfation of uronic acid-containing polysaccharides
JP2002542301A (ja) 1999-04-22 2002-12-10 アイトゲネシッシェ、テヒニッシェ、ホッホシューレ（エーテーハー） ヘパリン含有マトリックスからの増殖因子の制御放出
WO2001066164A1 (en) 1999-04-22 2001-09-13 Eidgenossisch Technische Hochschule Zurich Modified protein matrices
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6773723B1 (en) 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
GB0029847D0 (en) 2000-12-07 2001-01-24 Univ Bristol Preparation of spheroids
DE60236974D1 (de) 2001-07-26 2010-08-19 Transparent Inc Kultiviertes Zellkonstrukt mit Sphäroiden kultivierter Tierzellen und seine Verwendung
AU2003217700A1 (en) 2002-02-26 2003-09-09 Stelsys Llc Hepatocyte bioreactor system for long term culture of functional hepatocyte spheroids
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
CA2556169C (en) 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
FR2871379B1 (fr) * 2004-06-14 2006-09-29 Ifremer Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese
CN101068574B (zh) 2004-07-20 2012-07-18 伊索格尼斯股份有限公司 与自身抗原有关的自身免疫和疾病的特异性抑制
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
EP1886696A1 (en) 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
US8275594B2 (en) 2006-10-30 2012-09-25 The Regents Of The University Of Michigan Engineered scaffolds for intervertebral disc repair and regeneration and for articulating joint repair and regeneration
ES2322637B1 (es) 2007-06-26 2010-03-05 Universidad Del Pais Vasco Microparticulas de alginato modificado con rgd como sistema de liberacion de farmacos.
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2010030964A2 (en) 2008-09-12 2010-03-18 The Brigham And Women's Hospital, Inc. 3-dimensional multi-layered hydrogels and methods of making the same
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
JP6294666B2 (ja) * 2010-04-13 2018-03-14 イミュノバティブ セラピーズ，リミテッド 制御性ｔ細胞の阻害のための方法および組成物
WO2011163568A1 (en) 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
EP2678048B1 (en) 2011-02-22 2018-11-21 Institut National de la Sante et de la Recherche Medicale (INSERM) Nano-reservoirs technology for use in bone and/or cartilage regeneration
EP2816964B1 (en) 2012-02-21 2023-12-27 Ben-Gurion University of The Negev Research and Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
MX385999B (es) * 2013-06-18 2025-03-18 Replicel Life Sciences Inc Composiciones y métodos para tratamiento de la piel.
WO2017175229A1 (en) * 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Polysaccharide compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043050A2 (en) 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2011078990A1 (en) 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprising hyaluronan and at least one t cell induction agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomaterials, (2016), 80, p.11-19
J. Neuroimmunol., (1997), 75, [1-2], p.169-173

Also Published As

Publication number Publication date
IL260436B1 (en) 2023-04-01
WO2017118979A1 (en) 2017-07-13
EP3400074B1 (en) 2021-10-20
IL260436A (enExample) 2018-08-30
KR20180104646A (ko) 2018-09-21
EP3400074A4 (en) 2019-07-10
CN109069875B (zh) 2021-12-24
CN109069875A (zh) 2018-12-21
JP2019504832A (ja) 2019-02-21
US11123404B2 (en) 2021-09-21
US20190008924A1 (en) 2019-01-10
EP3400074A1 (en) 2018-11-14
IL260436B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7033066B2 (ja) 免疫寛容応答を生成する組成物及び方法
Mohammadi et al. Exosome loaded immunomodulatory biomaterials alleviate local immune response in immunocompetent diabetic mice post islet xenotransplantation
US20220047778A1 (en) Bioengineered scaffolds for modulation of immune system and the uses thereof
ES2769778T3 (es) Composiciones inmunomoduladoras
EP3065701B1 (en) Eluting matrix and uses thereof
US10580262B2 (en) Eluting matrix and uses thereof
US20160199450A1 (en) Scaffolds containing cytokines for tissue engineering
Orr et al. TGF-β affinity-bound to a macroporous alginate scaffold generates local and peripheral immunotolerant responses and improves allocell transplantation
CN105079792A (zh) Il-17在提高间充质干细胞免疫抑制功能中的应用
Liu et al. Impact of marine-based biomaterials on the immunoregulatory properties of bone marrow-derived mesenchymal stem cells: potential use of fish collagen in bone tissue engineering
Yuan et al. Chondrogenic differentiation and immunological properties of mesenchymal stem cells in collagen type I hydrogel
CA3189070A1 (en) Crosslinked hydrogel for immune checkpoint blockade delivery
US20260007724A1 (en) Methods and compositions for improving wound healing
Mohammadi et al. Exosome loaded immunomodulatory biomaterials alleviate local immune response in
Srinivasan et al. Host Response to Biomaterials
EP4551259A1 (en) Methods and compositions for improving wound healing
JP6429237B2 (ja) 免疫寛容部位形成剤及び免疫抑制性細胞の誘引剤
KR20230079403A (ko) 이식편 거부반응을 치료하기 위한 면역공학 생체물질
Su Design of Immunoactive Biomaterials for Therapeutic Applications
Kwee Biomaterial-based Helper T-cell Therapies for Ischemic Diseases
Bollyky et al. Research Article IL-10 Induction from Implants Delivering Pancreatic Islets and Hyaluronan
Farooqui The In Vitro Effects of Biomaterials on Lymphocyte Responses to an Allogeneic Challenge

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220225

R150 Certificate of patent or registration of utility model

Ref document number: 7033066

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees